OptimizeRx(OPRX) - 2025 Q1 - Quarterly Results

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - Q1 revenue of $21.9 million, increasing 11% year-over-year - Q1 gross profit increased 9% year-over-year to$ 13.3 million - Increases full year 2025 guidance to a revenue range between $101 million and$ 106 million and adjusted EBITDA range between $13 million and$ 15 million WALTHAM, Mass. – May 12, 2025 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions help ...